Needham Maintains Buy on Starling Oncology, Raises Price Target to $9
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice Target
Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.
Needham analyst Matthew Shea maintains Starling Oncology (NASDAQ:STLN) with a Buy and raises the price target from $7 to $9.